Susa Ventures

Susa Ventures is a San Francisco-based seed and Series A firm that has spent more than a decade backing data-defensible companies in unsexy categories, and its healthcare exposure fits squarely inside that broader thesis. Susa is not a healthcare specialist; it is a data and distribution specialist that finds healthcare companies particularly interesting when they have a real proprietary data moat or a network effect that compounds over time. That framing shapes which founders the firm engages and how the partners diligence them.

The declared healthcare sub-verticals are digital health and health IT software, with an AI lens. In practice that means Susa is interested in companies with structural data advantages: claims data, clinical data, operational data inside hospitals, or workflow data that becomes more valuable as the product is used. AI is treated less as a feature and more as a way to compound the data advantage. The firm tends to be less drawn to direct-to-consumer wellness, branded telehealth, or therapeutics, and more drawn to enterprise software that becomes harder to displace the longer it runs inside a customer.

Check sizes of $1M-$5M at seed and Series A position the firm as a credible co-lead or lead at the early stages, with the discipline to follow on selectively. Geographically the focus is the US, with meaningful concentration in the Bay Area but real openness to companies based in New York, Boston, and other healthcare hubs. The partners are willing to write into less obvious geographies when the data thesis is strong enough. The firm has historically maintained a relatively concentrated portfolio rather than a sprawling one, which means founders who are accepted typically get genuine attention.

The team is built around investors who think deeply about data, distribution, and durability. Diligence tends to be analytical and direct, with sharp questions about the structure of the data the company is collecting, who else can access it, how the network effect compounds, and how a defensible product evolves into a defensible company. Founders should be ready for that conversation rather than for a marketing-heavy pitch.

For founders, the practical read is that Susa is a strong early-stage partner for healthcare AI and IT companies whose advantage is rooted in data and distribution. It is less useful for consumer brand plays, for therapeutics, or for founders who do not have a clear data thesis. The engagement style is intellectually rigorous and supportive, with partners who tend to stay close to the companies they back and to lean in on follow-on rounds when the early traction confirms the original thesis. Founders building structurally defensible healthcare software with real data moats and looking for a sharp, concentrated seed partner will find Susa one of the more thoughtful options in the Bay Area early-stage landscape.